1-BOC-十氢-1,5-萘啶 | 1000931-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-BOC-十氢-1,5-萘啶
• 英文名称: tert-Butyl octahydro-1,5-naphthyridine-1(2H)-carboxylate
• 英文别名: tert-butyl 3,4,4a,5,6,7,8,8a-octahydro-2H-1,5-naphthyridine-1-carboxylate
• CAS: 1000931-58-7
• 化学式: C₁₃H₂₄N₂O₂
• mdl: MFCD09863462
• 分子量: 240.34
• InChiKey: NJASRKUXYJXBNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  331.7±15.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.923
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• Aminopyrimidine Kinase Inhibitors
  申请人：Baldino Carmen M.

  公开号：US20110152235A1

  公开（公告）日：2011-06-23

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

  揭示了化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径调节剂的用途。还揭示了用于治疗或预防一系列治疗适应症的用途，至少部分原因是由于酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径的异常生理活性。
• [EN] QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR<br/>[FR] COMPOSÉS DE QUINOLÉINE APPROPRIÉS POUR TRAITER LES AFFECTIONS SENSIBLES À LA MODULATION DES RÉCEPTEURS SÉROTONINERGIQUES 5-HT6
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009019286A1

  公开（公告）日：2009-02-12

  The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.

  本发明涉及公式（I）的新奎诺林化合物及其盐。这些化合物具有有价值的治疗性能，并特别适用于治疗对5-HT6受体调节产生反应的疾病。在公式（I）中，R是公式（R）的基团，其中*表示与喹啉基团的结合位点，A、B、X'、Y、Q、R1、R2、R3、R4、R5、m、n、p、q、Ra、Rb、X和Ar的定义如权利要求书中所述。
• [EN] PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS AMINE PYRAZOLOPYRIDINIQUES POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020052738A1

  公开（公告）日：2020-03-19

  The present invention relates to compounds of formula (I), wherein R1, R2, R3,R4 and X are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的化合物，其中R1，R2，R3，R4和X如此描述，以及它们的药学上可接受的盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR
  申请人：Turner Sean Colm

  公开号：US20130005703A1

  公开（公告）日：2013-01-03

  The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R 1 , R 2 , R 3 , R 4 , R 5 , m, n, p, q, R a , R b , X and Ar are as defined in claim 1 .

  本发明涉及公式（I）的新型喹啉化合物及其盐。该化合物具有有价值的治疗性能，特别适用于治疗对5-HT6受体调节有反应的疾病。在公式（I）中，R是公式（R）的基团，其中*表示与喹啉基团的结合位点，其中A、B、X'、Y、Q、R1、R2、R3、R4、R5、m、n、p、q、Ra、Rb、X和Ar如权利要求1所定义。
• Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor
  申请人：Turner Sean Colm

  公开号：US20100292271A1

  公开（公告）日：2010-11-18

  The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5 -HT 6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R 1 , R 2 , R 3 , R 4 , R 5 , m, n, p, q, R 1 , R b , X and Ar are as defined in claim 1.

  本发明涉及公式(I)的新型喹啉化合物及其盐。这些化合物具有有价值的治疗性质，特别适用于治疗对5-HT6受体调节有反应的疾病。在公式(I)中，R是公式(R)的一部分，其中*表示与喹啉基团的结合位点，而A、B、X'、Y、Q、R1、R2、R3、R4、R5、m、n、p、q、Rb、X和Ar的定义如权利要求书1所述。